-+ 0.00%
-+ 0.00%
-+ 0.00%

JP Morgan Maintains Overweight on BridgeBio Oncology, Lowers Price Target to $25

Benzinga·08/14/2026 16:16:55
Listen to the news
JP Morgan analyst Priyanka Grover maintains BridgeBio Oncology (NASDAQ:BBOT) with a Overweight and lowers the price target from $27 to $25.